Trade Cabaletta Bio, Inc. - CABA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.0812 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Cabaletta Bio Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 13.9294 |
| Open* | 13.9194 |
| 1-Year Change* | 67.96% |
| Day's Range* | 13.1894 - 14.1794 |
| 52 wk Range | 5.88-24.62 |
| Average Volume (10 days) | 857.80K |
| Average Volume (3 months) | 24.86M |
| Market Cap | 877.56M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.85M |
| Revenue | N/A |
| EPS | -1.71 |
| Dividend (Yield %) | N/A |
| Beta | 2.49 |
| Next Earnings Date | Mar 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 13.9294 | -0.9900 | -6.64% | 14.9194 | 14.9494 | 13.7594 |
| Apr 17, 2024 | 15.0994 | -1.1800 | -7.25% | 16.2794 | 16.2794 | 15.0794 |
| Apr 16, 2024 | 16.2694 | 0.4000 | 2.52% | 15.8694 | 16.3794 | 15.8194 |
| Apr 15, 2024 | 16.1294 | -0.8900 | -5.23% | 17.0194 | 17.4894 | 15.9394 |
| Apr 12, 2024 | 16.9994 | -0.4800 | -2.75% | 17.4794 | 18.2794 | 16.7994 |
| Apr 11, 2024 | 17.8694 | -0.1200 | -0.67% | 17.9894 | 17.9994 | 17.4394 |
| Apr 10, 2024 | 17.8194 | -0.2800 | -1.55% | 18.0994 | 18.4194 | 17.5094 |
| Apr 9, 2024 | 18.7994 | 0.9400 | 5.26% | 17.8594 | 18.9894 | 17.5894 |
| Apr 8, 2024 | 17.9994 | 0.9400 | 5.51% | 17.0594 | 18.1494 | 16.7494 |
| Apr 5, 2024 | 16.9294 | 1.0600 | 6.68% | 15.8694 | 17.0394 | 15.8194 |
| Apr 4, 2024 | 16.0694 | -0.2300 | -1.41% | 16.2994 | 17.3094 | 15.9494 |
| Apr 3, 2024 | 16.4094 | 0.1600 | 0.98% | 16.2494 | 16.6894 | 16.1594 |
| Apr 2, 2024 | 16.4494 | 0.1600 | 0.98% | 16.2894 | 16.6894 | 16.2894 |
| Apr 1, 2024 | 16.7694 | -0.1200 | -0.71% | 16.8894 | 16.8994 | 16.1994 |
| Mar 28, 2024 | 16.9894 | 0.0200 | 0.12% | 16.9694 | 17.4394 | 16.7794 |
| Mar 27, 2024 | 17.0894 | 0.0900 | 0.53% | 16.9994 | 17.1094 | 16.5694 |
| Mar 26, 2024 | 16.8994 | 0.0500 | 0.30% | 16.8494 | 17.0894 | 16.5794 |
| Mar 25, 2024 | 16.7394 | -0.7000 | -4.01% | 17.4394 | 17.8394 | 16.6294 |
| Mar 22, 2024 | 17.2994 | 0.4800 | 2.85% | 16.8194 | 18.3794 | 16.8094 |
| Mar 21, 2024 | 17.4894 | -0.4800 | -2.67% | 17.9694 | 18.0594 | 16.2794 |
Cabaletta Bio, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, May 9, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 Cabaletta Bio Inc Earnings Release Q1 2024 Cabaletta Bio Inc Earnings ReleaseForecast -Previous - |
| Friday, May 31, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event Cabaletta Bio Inc Annual Shareholders Meeting Cabaletta Bio Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 54.139 | 46.313 | 33.833 | 18.683 | 6.193 |
| Selling/General/Admin. Expenses, Total | 14.839 | 13.819 | 12.457 | 7.012 | 1.726 |
| Research & Development | 39.3 | 32.494 | 21.376 | 11.671 | 4.467 |
| Operating Income | -54.139 | -46.313 | -33.833 | -18.683 | -6.193 |
| Interest Income (Expense), Net Non-Operating | 1.164 | 0.024 | 0.494 | 1.74 | 0.235 |
| Other, Net | 0 | -6.244 | |||
| Net Income Before Taxes | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income After Taxes | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income Before Extra. Items | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Income Available to Common Excl. Extra. Items | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Income Available to Common Incl. Extra. Items | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Diluted Net Income | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Diluted Weighted Average Shares | 29.3429 | 25.7373 | 23.1452 | 24.034 | 22.5529 |
| Diluted EPS Excluding Extraordinary Items | -1.80538 | -1.79852 | -1.44043 | -0.92656 | -0.54104 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -1.80538 | -1.79852 | -1.44043 | -0.92656 | -0.54104 |
| Total Adjustments to Net Income | 0 | -5.326 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 15.89 | 16.956 | 16.302 | 11.778 | 13.06 |
| Selling/General/Admin. Expenses, Total | 4.093 | 4.521 | 3.902 | 3.562 | 3.546 |
| Research & Development | 11.797 | 12.435 | 12.4 | 8.216 | 9.514 |
| Operating Income | -15.89 | -16.956 | -16.302 | -11.778 | -13.06 |
| Interest Income (Expense), Net Non-Operating | 1.403 | 1.102 | 0.61 | 0.351 | 0.15 |
| Net Income Before Taxes | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income After Taxes | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income Before Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Income Available to Common Excl. Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Income Available to Common Incl. Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Diluted Net Income | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Diluted Weighted Average Shares | 39.1728 | 35.4492 | 30.4136 | 29.014 | 28.9869 |
| Diluted EPS Excluding Extraordinary Items | -0.36982 | -0.44723 | -0.51595 | -0.39384 | -0.44537 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.36982 | -0.44723 | -0.51595 | -0.39384 | -0.44537 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 108.834 | 124.541 | 113.535 | 140.552 | 33.994 |
| Cash and Short Term Investments | 106.547 | 122.222 | 108.662 | 136.204 | 33.017 |
| Cash & Equivalents | 81.607 | 122.222 | 101.429 | 136.204 | 33.017 |
| Prepaid Expenses | 2.287 | 2.319 | 4.873 | 4.348 | 0.977 |
| Total Assets | 116.968 | 126.336 | 114.724 | 141.468 | 34.174 |
| Other Long Term Assets, Total | 0.565 | 0.357 | 0.299 | 0.101 | 0.18 |
| Total Current Liabilities | 9.489 | 8.38 | 5.18 | 3.147 | 0.943 |
| Accounts Payable | 2.463 | 2.333 | 1.243 | 0.92 | 0.603 |
| Accrued Expenses | 5.694 | 2.977 | 2.445 | 1.522 | 0.121 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.332 | 3.07 | 1.492 | 0.705 | 0.219 |
| Total Liabilities | 12.448 | 8.38 | 5.18 | 3.147 | 0.943 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 104.52 | 117.956 | 109.544 | 138.321 | 33.231 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 43.921 |
| Common Stock | 0.00029 | 0.00029 | 0.00024 | 0.00024 | 0 |
| Additional Paid-In Capital | 270.129 | 230.543 | 175.836 | 171.28 | 1.762 |
| Retained Earnings (Accumulated Deficit) | -165.562 | -112.587 | -66.298 | -32.959 | -12.452 |
| Total Liabilities & Shareholders’ Equity | 116.968 | 126.336 | 114.724 | 141.468 | 34.174 |
| Total Common Shares Outstanding | 29.4451 | 28.9271 | 24.0628 | 24.034 | 22.5529 |
| Property/Plant/Equipment, Total - Net | 7.569 | 1.438 | 0.89 | 0.815 | |
| Other Equity, Total | -0.04729 | -0.00029 | 0.00576 | -0.00024 | |
| Short Term Investments | 24.94 | 0 | 7.233 | ||
| Property/Plant/Equipment, Total - Gross | 9.938 | 2.629 | 1.348 | ||
| Accumulated Depreciation, Total | -2.369 | -1.191 | -0.458 | ||
| Other Liabilities, Total | 2.959 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 166.178 | 177.572 | 95.734 | 108.834 | 88.175 |
| Cash and Short Term Investments | 164.391 | 176.328 | 93.845 | 106.547 | 85.895 |
| Cash & Equivalents | 115.501 | 128.072 | 93.845 | 81.607 | 61.163 |
| Short Term Investments | 48.89 | 48.256 | 0 | 24.94 | 24.732 |
| Prepaid Expenses | 1.787 | 1.244 | 1.889 | 2.287 | 2.28 |
| Total Assets | 173.287 | 184.637 | 103.447 | 116.968 | 91.675 |
| Property/Plant/Equipment, Total - Net | 6.125 | 6.38 | 7.132 | 7.569 | 2.811 |
| Other Long Term Assets, Total | 0.984 | 0.685 | 0.581 | 0.565 | 0.689 |
| Total Current Liabilities | 10.616 | 8.482 | 9.305 | 9.489 | 5.801 |
| Accounts Payable | 3.62 | 2.341 | 3.955 | 2.463 | 1.333 |
| Accrued Expenses | 5.632 | 4.157 | 3.176 | 5.694 | 2.268 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.364 | 1.984 | 2.174 | 1.332 | 2.2 |
| Total Liabilities | 12.364 | 10.496 | 11.796 | 12.448 | 5.801 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 160.923 | 174.141 | 91.651 | 104.52 | 85.874 |
| Common Stock | 0.00042 | 0.00039 | 0.00031 | 0.00029 | 0.00029 |
| Additional Paid-In Capital | 373.295 | 370.047 | 273.067 | 270.129 | 235.953 |
| Retained Earnings (Accumulated Deficit) | -212.351 | -195.903 | -181.416 | -165.562 | -149.87 |
| Other Equity, Total | -0.02142 | -0.00339 | -0.00031 | -0.04729 | -0.20929 |
| Total Liabilities & Shareholders’ Equity | 173.287 | 184.637 | 103.447 | 116.968 | 91.675 |
| Total Common Shares Outstanding | 41.6602 | 39.7937 | 31.341 | 29.4451 | 29.014 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 1.748 | 2.014 | 2.491 | 2.959 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Cash From Operating Activities | -46.38 | -34.109 | -26.77 | -16.045 | -4.661 |
| Non-Cash Items | 9.716 | 5.866 | 4.507 | 2.3 | 8.005 |
| Changes in Working Capital | -4.299 | 5.581 | 1.708 | -1.506 | -0.464 |
| Cash From Financing Activities | 32.982 | 48.903 | -0.024 | 119.925 | 37.677 |
| Issuance (Retirement) of Stock, Net | 32.982 | 48.903 | -0.024 | 119.925 | 37.677 |
| Net Change in Cash | -40.615 | 20.793 | -34.775 | 103.187 | 33.016 |
| Cash From Operating Activities | 1.178 | 0.733 | 0.354 | 0.104 | |
| Cash From Investing Activities | -27.217 | 5.999 | -7.981 | -0.693 | |
| Capital Expenditures | -2.453 | -1.166 | -0.635 | -0.693 | |
| Other Investing Cash Flow Items, Total | -24.764 | 7.165 | -7.346 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -15.854 | -52.975 | -37.283 | -25.856 | -12.946 |
| Cash From Operating Activities | -12.608 | -46.38 | -34.249 | -24.335 | -12.809 |
| Cash From Operating Activities | 0.365 | 1.178 | 0.82 | 0.457 | 0.219 |
| Non-Cash Items | 3.023 | 9.716 | 5.142 | 3.466 | 1.763 |
| Changes in Working Capital | -0.142 | -4.299 | -2.928 | -2.402 | -1.845 |
| Cash From Investing Activities | 24.62 | -27.217 | -26.901 | -50.809 | -49.911 |
| Capital Expenditures | -0.38 | -2.453 | -2.137 | -1.045 | -0.147 |
| Other Investing Cash Flow Items, Total | 25 | -24.764 | -24.764 | -49.764 | -49.764 |
| Cash From Financing Activities | 0.226 | 32.982 | 0.091 | 0.091 | 0.051 |
| Issuance (Retirement) of Stock, Net | 0.458 | 32.982 | 0.091 | 0.091 | 0.051 |
| Net Change in Cash | 12.238 | -40.615 | -61.059 | -75.053 | -62.669 |
| Financing Cash Flow Items | -0.232 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cabaletta Bio, Inc. Company profile
About Cabaletta Bio Inc
Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.
| Industry: | Bio Therapeutic Drugs |
2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com